Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.

ABSTRACT:

Background

The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to "guide" application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone.

Objectives

The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial.

Methods

A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality duri

SUBMITTER: Januzzi JL 

PROVIDER: S-EPMC6719723 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature